Ciprofibrate

环丙贝特

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCiprofibrate
Drug Alias NameCiprofibratum洛贝特CiprofibratoModalimLipanor +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsHyperlipidemiasGlucose Metabolism DisordersHeart Diseases
Global Approved IndicationsHyperlipidemias
Approved Indications in ChinaHyperlipidemias
Original Approved Country/TerritoryN/A
Original Approved Date1985/01/01
Country/TerritoryNetherlandsMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMaastricht University Medical Center
Active IndicationsHyperlipidemias
Inactive IndicationsGlucose Metabolism DisordersHeart Diseases

Other Information

ATC CodeC10AB08
Related LinksWikipediaKEGG